Aberdeen Group plc Buys Shares of 913,593 BioCryst Pharmaceuticals, Inc. $BCRX

Aberdeen Group plc acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 913,593 shares of the biotechnology company’s stock, valued at approximately $7,126,000. Aberdeen Group plc owned approximately 0.43% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Focus Partners Wealth purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth $77,000. Farther Finance Advisors LLC increased its stake in BioCryst Pharmaceuticals by 326.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after buying an additional 8,109 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth $81,000. Vestmark Advisory Solutions Inc. purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth $81,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in BioCryst Pharmaceuticals in the 3rd quarter worth $81,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $9.78 on Thursday. The company’s fifty day moving average price is $8.19 and its 200-day moving average price is $7.57. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The firm has a market capitalization of $2.45 billion, a PE ratio of 8.15 and a beta of 0.70.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.07 by $1.05. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The company had revenue of $163.28 million for the quarter, compared to the consensus estimate of $151.32 million. During the same quarter in the prior year, the company earned ($0.13) EPS. BioCryst Pharmaceuticals’s quarterly revenue was up 209.1% on a year-over-year basis. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the sale, the insider directly owned 400,703 shares of the company’s stock, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Evercore assumed coverage on BioCryst Pharmaceuticals in a research report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company. Royal Bank Of Canada cut their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. HC Wainwright raised their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Finally, Weiss Ratings raised shares of BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Ten analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $19.64.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.